We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-1.96%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$114M
AUM Growth
-$29.8M
Cap. Flow
-$27M
Cap. Flow %
-23.68%
Top 10 Hldgs %
42.25%
Holding
85
New
11
Increased
13
Reduced
16
Closed
19

Top Buys

Rank Stock Value
1
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$4.51M
2
IBB icon
iShares Biotechnology ETF
IBB
+$2.38M
3
BPMC
Blueprint Medicines
BPMC
+$2.19M
4
CDTX
Cidara Therapeutics
CDTX
+$1.66M
5
ADXS
Advaxis Inc
ADXS
+$1.57M

Top Sells

Rank Stock Value
1
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
+$15M
2
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
+$9.26M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$2.15M
4
BSTC
BioSpecifics Technologies Corp.
BSTC
+$1.81M
5
TSRO
TESARO, Inc.
TSRO
+$1.77M

Sector Composition

Rank Sector Weight
1 Healthcare 81.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INNL
76
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
– –
-100,000
Closed -$581K
WINT
77
DELISTED
Windtree Therapeutics Inc
WINT
– –
-480,833
Closed -$1.23M
VTAE
78
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
– –
-715,988
Closed -$15M
CYNA
79
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
– –
-230,201
Closed -$9.26M
IMDZ
80
DELISTED
Immune Design Corp.
IMDZ
– –
-40,000
Closed -$303K
ETRM
81
DELISTED
EnteroMedics Inc.
ETRM
– –
-476
Closed -$5K
1 2 3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
CPW
Cove Private Wealth Oyster Bay Cove, New York $440M AUM 27.56% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return

DAFNA Capital Management's Q4 2016 Portfolio in Review

As of Q4 2016, DAFNA Capital Management held 85 positions worth $114M, down 21% from $144M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

DAFNA Capital Management withdrew a net $27M in Q4 2016, closing 19 positions and reducing 16 holdings. Its most notable exit was VITAE PHARMACEUTICALS INC COMMON STOCK, an estimated $15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 68% a quarter earlier.

Against the trend, DAFNA Capital Management opened a new position in Viracta Therapeutics, Inc. Common Stock worth $4.1M.

  • DAFNA Capital Management's largest Q4 2016 buy was Viracta Therapeutics, Inc. Common Stock: 32,388 shares worth $4.1M.
  • DAFNA Capital Management added most to Alder Biopharmaceuticals in Q4 2016, an estimated $1.45M increase.
  • DAFNA Capital Management's biggest Q4 2016 reduction was TESARO, Inc., cutting an estimated $1.77M.
  • DAFNA Capital Management fully exited VITAE PHARMACEUTICALS INC COMMON STOCK in Q4 2016, selling an estimated $15M.
  • DAFNA Capital Management's ten largest holdings make up 42% of its $114M portfolio in Q4 2016.
  • DAFNA Capital Management opened 11 new positions and closed 19 in Q4 2016.
  • DAFNA Capital Management's portfolio value fell 21% quarter-over-quarter to $114M.

Based on DAFNA Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.